Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Partners of the Pierre Fabre Group: from health to beauty
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Partners of the Pierre Fabre Group: from health to beauty
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Puma regains China rights to Nerlynx and amends deal with Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma and CANBridge cancel licensing deal for $20m
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
Puma regains China rights to Nerlynx and amends deal with Fabre
Accord entre Pierre Fabre et Puma Biotechnology
Blue March: Pierre Fabre supports colorectal cancer awareness month
Fight against cancer : our therapeutic responses | Pierre Fabre
THE FACES OF BREAST CANCER
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotech Expands Pierre Fabre License to Add Countries
Pierre Fabre engagements | NERLYNX
Puma regains China rights to Nerlynx and amends deal with Fabre
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
